MarketVIEW: Chlamydia trachomatis vaccines - 21 News Now, More Local News for Youngstown, Ohio -

Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.

SOURCE Reportlinker

NEW YORK, Feb. 18, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

MarketVIEW: Chlamydia trachomatis vaccines

http://www.reportlinker.com/p0961709/MarketVIEW-Chlamydia-trachomatis-vaccines.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Chlamydia trachomatis (CT) is an intracellular Gram-negative bacterium and a leading cause worldwide of sexually-transmitted disease and preventable blindness. The pathogen is a major cause of serious reproductive complications in the female with outcomes such as pelvic inflammatory disease (PID) and ectopic pregnancies.

Although diagnosed infections with Chlamydia trachomatis are curable with antibiotic therapy the vast majority infections are "silent" and unrecognized. This is of concern due to continued transmission especially among individuals below 30 years of age. Prophylatic vaccines could prevent CT primary infection, reinfection or lessen the incidence and severity of PID, or similar long-term sequelae. A key question for vaccine manufacturers is whether a CT vaccine would be deployed alongside HPV vaccines in the preadolescent population, thus providing a sizeable commercial opportunity. 

This MarketVIEW product gives a comprehensive vaccine value ($USD/volume (000s) forecast for a putative CT vaccine until 2035. The model includes LO/BASE/HI forecast scenarios so the user can visualize the commercial impact of differing targetting/competitive and pricing scenarios. This product is an essential component of any commercial opportunistic assessment focused on new adolescent vaccines. 

THIS PRODUCT IS A SUMMARY PRESENTATION + MODEL Contents – Summary presentation (MS PowerPoint based)Executive SummaryCommercial model – key outputsTotal available demand: Chlamydia vaccine, global, (000s doses)Total available demand: Chlamydia vaccine, high-income markets, (000s doses)Total available demand: Chlamydia vaccine, emerging markets, (000s doses)Total available market: Chlamydia vaccine, global, ($ 000s)Total available market: Chlamydia vaccine, by market, ($ 000s)Total available market: Chlamydia vaccine, price sensitivity analysis, ($ 000s)Chlamydia vaccine: country volume analysis, 2025 (000s doses)Chlamydia vaccine: country value analysis, 2025 ($ 000s)The role of a CT vaccineCommercial model – key assumptionsPricingModel forecast comparisons: June 2011 v currentChlamydia vaccine opportunity: target product profileOverall commercial model assumptions per countryChlamydia trachomatis: brief backgroundClinical featuresChlamydia trachomatis: natural history of infectionChlamydia trachomatis: global incidenceChlamydia trachomatis: global prevalenceUS epidemiologyUK epidemiologyReasons for increasing incidencePotential impact of a CT vaccineCompetitor landscape: overviewCompetitive environment: major playersChlamydia trachomatis vaccine – HPV, a relevant case study?HPV vaccines: analysis of country uptakeBibliographyDisclaimerAbout VacZine Analytics

PAGES: ~57 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model (MS Excel-based)Title SheetScenario definitionValue Scenario AnalysisValue Summary (Western)Volume Summary (Western)Value Summary (Emerging)Volume Summary (Emerging)Charts – volume (Western)Charts – value (Western)Charts – value/volume (Western)Females (Western) ?US (13 yrs/ 14 - 18 yrs)CanadaUKFranceGermanyItalySpainOther EUAustraliaJapanFemales (Emerging) ?BrazilRussiaIndiaChinaMexicoPopulation databaseCompetition – IP landscapeAssumptions – major marketsBack pageAbout VacZine AnalyticsDisclaimerWORKSHEETS: ~65

To order this report:: MarketVIEW: Chlamydia trachomatis vaccines

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

 

©2012 PR Newswire. All Rights Reserved.